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Accepted 29 June 2016DNA sequencing continues to evolve quickly even after N30 years. Many new platforms suddenly appeared and
former established systems have vanished in almost the same manner. Since establishment of next-generation
sequencing devices, this progress gains momentum due to the continually growing demand for higher through-
put, lower costs and better quality of data. In consequence of this rapid development, standardized procedures
and data formats as well as comprehensive quality management considerations are still scarce. Here, we listed
and summarized current standardization efforts and quality management initiatives from companies, organiza-
tions and societies in form of published studies and ongoing projects. These comprise on the one hand quality
documentation issues like technical notes, accreditation checklists and guidelines for validation of sequencing
workﬂows. On the other hand, general standard proposals and quality metrics are developed and applied to
the sequencing workﬂow steps with the main focus on upstream processes. Finally, certain standard develop-
ments for downstream pipeline data handling, processing and storage are discussed in brief. These standardiza-
tion approaches represent a ﬁrst basis for continuing work in order to prospectively implement next-generation
sequencing in important areas such as clinical diagnostics, where reliable results and fast processing is crucial.
Additionally, these efforts will exert a decisive inﬂuence on traceability and reproducibility of sequence data.
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The initial sequencing methods were developed by Maxam and
Gilbert as well as Sanger and Coulson with the latter being almost the
only method in use for N30 years (Hutchison, 2007; Schuster, 2008).
These methods became popular, because they represented the ﬁrst
approaches for unraveling DNA nucleotide sequences. Since 2005,
second-generation sequencing technologies, termed as next-generation
sequencing (NGS), allow to investigatewhole genomes or transcriptomes
from different organisms in relatively short time (Morozova and Marra,
2008; Pareek et al., 2011). The promise to get an insight into gene func-
tion and regulation led to an increasing number of methods and sys-
tems in the last ten years. These new methods and systems steadily
increased in throughput, broad in ﬁeld of applications and resulted in
better quality of data (Metzker, 2010). Consequently, a big market has
established comprising sequencing services providers and sequencing
platform manufacturers. By implication, NGS exerts nowadays an
increasing impact on academic research, diagnostics and industry. In
particular, the establishment of NGS in diagnostics will entail many
advantages such as higher throughput of patient samples and thus
obtaining faster results and decreased costs (Dietel et al., 2015;
Meldrum et al., 2011), because today's medical questions are focusing
on therapy opportunities for complex genetic diseases (Boycott et al.,
2013; ten Bosch and Grody, 2008). Especially in oncology, the perspec-
tive of ﬁnding a universal agent in form of a single pharmaceutical drug
is obsolete and there is an increasing demand for new innovations
regarding appropriate therapeutic treatments in order to promote the
upcoming ﬁeld of personalized medicine (Ross and Cronin, 2011). Un-
fortunately, the current high costs of NGS and uncertainty of data qual-
ity (O'Rawe et al., 2015) precludes the unfettered use in diagnostics at
this stage and appropriate projects are neither still not certiﬁed by the
US Food and Drug Administration (FDA) (Gargis et al., 2012) nor regu-
lated under the Clinical Laboratory Improvement Amendments (CLIA)
guidelines (Westgard and Westgard, 2006). Moreover, the implemen-
tation of guidelines often collides with individual demands and issues
of single laboratories as well as organizations and many research units
have little or any experience with quality management (QM) and qual-
ity assurance (QA). In order to change this, the standardization and sim-
pliﬁcation of NGSworkﬂows is a central requirement, involvingQMand
QA methods. Standards act as basic guidelines to ensure comparability
and exchange of experimental data conducive to accelerate the innova-
tion process and aid improvement of transferability, transparency and
reproducibility of results. Furthermore, standardization potentially
realizes a higher turnover bydecreasing costs, therefore enabling an im-
proved ﬁnancial planning and scheduling and thus a possible expansion
of services in an industrial context. However, standardization is a com-
plex topic characterized by several problems and challenges like failure
of initializing developed standards, missing consensus and deadlocks as
well as incompatible implementations of ﬁnished standards (Cargill,
2011). In particular, the formulation of NGS standards requires
additionally an extensive collection and evaluation of appropriate
platform-dependent and independent information as well as compara-
tive analysis of different sequencing systems. To comply with afore-
mentioned points, our aim was to identify previously established
standards, recommendations and guidelines for workﬂows, generally
addressing genomic DNA sequencing, and the corresponding QM and
QA opportunities, which are summarized within the framework ofthis article. The results gained from successful standardization of NGS
may transfer to other ﬁelds in life sciences. An overview of the general
NGS workﬂow annotated with single steps and appropriate QC check-
points is given in Fig. 1.
2. Quality management (QM) and quality assurance (QA) in NGS
A good starting point in standardization measures is the introduc-
tion of quality documentation. Frequently, there is an obvious lack of
such documentation within sequencing experiments. Thus, it is crucial
to develop and establish procedure-, operating- and inspection instruc-
tions as well as quality records. Furthermore, veriﬁcation documents,
particularly for providing a string of documents for the veriﬁable origin
of sequencing data is an essential point. Especially the quality records
could act as a certiﬁcate for customers and the general documentation
would improve the traceability and transparency with the aim to
prove the reliability of results. Another important parameter in QM con-
siderations is the QA. A QA program should contain predetermined
quality control (QC) checkpoints for monitoring QA and an extensive
documentation including, among others, used devices, reagent lot num-
bers and any deviation from standard procedures (Gargis et al., 2012;
Rehm et al., 2013). Moreover, the QA program should contain QC
methods for contamination identiﬁcation at several stages within the
sequencing workﬂow. These stages comprise the initial sample evalua-
tion, the fragmentation step, the ﬁnal library assessment, the monitor-
ing of error rates during the sequencing process and the raw data
analysis with focus on read quality (Rehm et al., 2013).
2.1. The technical note (TN) as a QA method to fulﬁll QM documentation
In order to address the aspects,mentioned in Section 2, the establish-
ment of a TN is recommended. The TN acts as a preventive QA method,
respectively a guideline to avoid common problems- and error-sources
like the performance of single preparation steps in different laboratories
or companies, and to remedy the lack of documentation. It is conceivable
as a docket or inspection record, which is permanently carried along in
order to ensure comprehensive QMdocumentation. After completion of
a sequencing project, the TN represents additionally a quality certiﬁcate
for delivery to the customer. A generic TN for the sample fragmentation
step is shown in the Appendix (see Appendix A — Table A.1).
2.2. Laboratory accreditation checklist requirements by the College of
American Pathologist's (CAP) NGS work group
The CAP NGSWork Group alsoworks onmeans of quality documen-
tation, but in a broader context, overarching general QA. They devel-
oped 18 laboratory accreditation checklist requirements for upstream
analytic processes and downstream bioinformatics solutions for NGS
in clinical applications (Aziz et al., 2015). These requirementswere pub-
lished within CAP's molecular pathology checklist (MOL) and include
new standards for documentation, validation, QA, conﬁrmatory testing,
exception logs, monitoring of upgrades, variant interpretation and
reporting, incidental ﬁndings, data storage, version traceability and
data transfer conﬁdentiality. Thewet bench process compriseworkﬂow
steps such as handling of patient samples, extraction of nucleic acids,
fragmentation, bar coding, optional enrichment of targets, adaptor liga-
tion, ampliﬁcation, library preparation, ﬂow cell loading and generation
Fig. 1. Overview of the general NGS workﬂow. The main steps library and template preparation, enrichment, sequencing and data analysis are divided into substeps containing
recommendations for checkpoints which are proposed for QC.
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process are summarized in the Appendix (see Appendix A — Table A.2).
2.3. Guidelines for validation of sequencing workﬂows in clinical
applications
The promising establishment of NGS into clinical practice led to a
wealth of considerations regarding the formulation of strict guidelines
and regulations by different bodies (Bennett and Farah, 2014). One of
the ﬁrst legislated guidelines are the “NGS guidelines for somatic genet-
ic variant detection”, provided by the New York State Department of
Health (http://www.wadsworth.org/sites/default/ﬁles/WebDoc/
1300145166/NextGenSeq_ONCO_Guidelines.pdf). These guidelines
include validation requirements and usage of reference materials. The
former covers key performance indicators such as accuracy (recom-
mended minimum of 50 samples composed of different material
type), robustness (likelihood of assay success), precision (recommend-
ed minimum of three positive samples for each variant type), repeat-
ability and reproducibility (ability to return identical results under
identical or changed conditions) as well as analytical sensitivity and
speciﬁcity (positive and negative percent of results compared to gold
standard). Accuracy, sensitivity and speciﬁcity in NGS assays are based
on depth of coverage and quantity of reads associated with a respective
base call (Gargis et al., 2012). Other validation parameters like repeat-
ability and reproducibility, which are required elements for establishing
precision in NGS tests, must be determined by sequencing the same ref-
erence sequence several times under same conditions (repeatability)
respectively under changed conditions (reproducibility), i.e. processing
the upstream pipeline in multiple laboratories while utilizing different
devices (Gargis et al., 2012). Together with both reportable and refer-
ence range the aforementioned validation requirements represent addi-
tionally the performance characteristics as published in the CLIA
guidelines (Westgard and Westgard, 2006). The clinical laboratory de-
mands are divided into QA, validation, data, QC and reports, while thequalitymanagement system (QMS) is characterized by a three tier hier-
archy including policies, standard operating procedures (SOP) and
records. However, the main focus of QM systems for clinical NGS appli-
cations relies on SOP's. In addition, the proposed criteria for platform se-
lection are total sequence capacity, sequence read length, sequence run
time and the ﬁnal quality and accuracy. These criteria are also essential
for performance optimization approaches. While the QA serves as
establishment of quality infrastructure, the QC is valuable to conﬁrm
testing outputs against requirements. Finally, the recommended QC
reference materials are no-template controls (NTC), which have to be
embedded into all ampliﬁcations steps, the negative control for initial
and periodically validation and the positive/sensitivity control,
which must be determined for each sequencing run (https://www.
horizondiscovery.com/reference-standards/what-are-reference-
standards/quality-controlled/new-york-state-guidelines). A similar
approach was performed by Gargis et al. who developed principles,
guidelines, standards as well as recommendations for the implementa-
tion of NGS into diagnostic laboratories within the Nex-StoCT project
(Next Generation Sequencing - Standardization of Clinical Testing)
(Gargis et al., 2012). Amajor obstacle in NGS standardization represents
the absence of an established Proﬁciency Testing (PT) system, which
causes lack of error identiﬁcation, missing indication of QC problems
as well as aggravated veriﬁcation of test performance in laboratories.
Therefore, the Nex-StoCT workgroup developed and published rec-
ommendations for the structure of a novel NGS PT program. These
recommendations comprise on the one hand the establishment of a
methods-based assessment for test performance in order to improve
inter-laboratory comparisons by using exclusively genomic DNA from
well-characterized cell lines as PT samples. On the other hand, they sug-
gested the utilization of electronic data as PT samples to evaluate the
downstream bioinformatics abilities of different users. Hence, the
Nex-StoCT group proposed PT opportunities for both wet and dry labo-
ratory pipelines thus covering the entire NGS workﬂow (Gargis et al.,
2012).
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Next to the aforementioned efforts there are other standardization
approaches, especially from public institutes and societies. The US
National Institute of Standards and Technology (NIST) focused on stan-
dardization of sample preparationwithin the framework of very diverse
projects. Themost promising ongoing project is the “Genome in a Bottle
Consortium” (https://sites.stanford.edu/abms/giab). This consortium
centers its attention on adapting procedures established for whole
genome sequencing to the clinical environment by investigation of ref-
erence data, methods and standards for NGS. Another standardization
approach is running by the Association of Biomolecular Resource
Facilities (ABRF), a network between different research departments
which address several biomolecular issues regarding standardization
and optimization with the objective to develop guidelines. Especially
the ABRF-NGS group has to be taken into account, due to their work
on identiﬁcation of optimal methods and strategies for NGS projects as
well as performance evaluation of different NGS platforms. The main
study of this work group is divided into two phases involving RNA se-
quencingwith focus on utilizing reference samples such as standardized
genomic DNA and synthetic spike-in RNA controls (Li et al., 2014; Tighe
et al., 2013). The basis of the aforementioned ABRF study represents the
MicroArray Quality Control Project (MAQC), which addressed the reli-
ability and reproducibility of cross-platform gene expression analysis
as well as development of standards and quality guidelines (MAQC
Consortium et al., 2006). Especially the third phase of MAQC has to be
considered, which is called Sequencing Quality Control (SEQC/MAQC-
III) (SEQC/MAQC-III Consortium, 2014). SEQC/MAQC-III centers on
evaluation of technical performance between different NGS platforms
by establishing benchmarks with reference samples.
4. Standard proposals for general sequencing workﬂows
4.1. Composition of NGS workﬂows
All NGS workﬂows can be divided into pre-analytical, analytical and
post-analytical process steps, where different standards are applicable.
While pre-analytical standards aim at quality, format and amount of
specimen/sample, which should be documented in detail, the analytical
standards consider the proof of these aspects, concerning DNA/RNA ex-
traction, quantiﬁcation and purity determination via ﬂuorometry or
spectrophotometry. If a sample does notmeet the deﬁnedminimum re-
quirements, the ﬁrst most recommended way is to refuse processing of
the sample, respectively order a new one (Rehmet al., 2013). Therefore,
Paciﬁc Biosciences deﬁned ﬁve speciﬁc questions regarding the overall
sample characterization in order to ensure appropriate QC procedures
(http://jgi.doe.gov/wp-content/uploads/2013/11/Importance-of-
Sample-QC.pdf). Firstly, they require knowing the original source of
the sample (blood, tissue, etc.). Secondly, they request which methods
were used to isolate the sample and thirdly, which quantiﬁcation was
performed (Qubit or NanoDrop). The last both points address questions
such as, if there was a quality assessment via gel electrophoresis and
whether a clean-up procedure took place before shearing.
4.2. Standard proposals for sample preparation step
Ensuring a good DNA/RNA quality begins already during isolation
and extraction. It is required to keep the majority of incubation steps
at lower temperatures (b60 °C), inhibit or buffer possible nuclease
activity while storing DNA/RNA samples permanently on ice and avoid
repeated freeze-thawed cycles. (http://www.mscience.com.au/
upload/pages/pacbio/technical-note—experimental-design-for-
microbial-assembly-2012.pdf). Furthermore, it has to be taken into
account, that there are some special sample quality requisitions for
third-generation sequencing systems like Paciﬁc Biosciences RS II,
owing to omission of DNA ampliﬁcation. These requisitions comprise,among others, double-stranded format of DNA, prevention of pH ex-
tremes (b6/N9), absence of chelating agents, detergents, divalent
metal cations, denaturants or RNA, respectively carryover contaminants
from starting material (http://www.umich.edu/~caparray/products/
ngs/pacbio/Paciﬁc%20Biosciences%20Template%20Preparation%20and%
20Sequencing.pdf). The quality assessment should yield an OD260/280
ratio of 1.8 to 2.0 and an OD260/230 ratio of 2.0 to 2.2 with latter being
an additional value for purity determination. Moreover, it is recom-
mended to perform an initial DNA damage repair for genomic DNA se-
quencing applications and the quality of DNA should be always assessed
prior library preparation (i.e. via capillary gel electrophoresis) (http://
www.pacb.com/wp-content/uploads/2014/04/TemplatePreparation.
pdf). This makes it obvious that the DNA input amount as well as follow-
ing ampliﬁcation steps are major bias-related factors. Dependent on ap-
plication it is recommend using 30–50 ng of DNA input and omission of
PCR to avoid e.g. GC bias during the library preparation (Chen et al., 2014).
4.3. Quality evaluation of formalin-ﬁxed, parafﬁn-embedded (FFPE) RNA
samples
Commonly used is the RNA Integrity Number (RIN) for the quality
evaluation of RNA calculated by the 28S peak area divided by the 18S
peak area and an undisclosed variable (Schroeder et al., 2006). As an al-
ternative the DV200 is a reliable QC value especially for quantiﬁcation of
FFPE RNA samples, which is calculated straightforward via e.g. Agilent
Bioanalyzer or Advanced Analytical Fragment Analyzer and involves
the complete electropherogram above fragment sizes of 200 bases
(=smear analysis) (Wang et al., 2016). On the one hand, a high per-
centage of fragments N200 nucleotides represents a high RNA integrity
and thus a better quality. On the other hand, a low percentage relates to
higher degradation and lower quality. The DV200 shows a considerably
higher reliability in comparison to RIN regarding RNA quality determi-
nation and thus allows the preparation of valuable libraries out of
poor source material (Eikrem et al., 2016).
4.4. Standard devices for sample quality assessment
There are two different devices often stated in NGS vendor manuals
respectively sequencing protocols, frequently found in nearly every lab-
oratory and thus almost exclusively used for QC in sequencing projects.
The ﬁrst is the capillary gel electrophoresis, which is embedded in the
overwhelmingmajority of projects and studies for investigation of frag-
ment size distribution as well as ﬁnal library quality assessment
(Borgström et al., 2011). Therefore, such device like Agilent Bioanalyzer
can be considered as an unofﬁcial standard for QC and the obtained re-
sults should be deposited in order to fulﬁll good QM documentation. To
determine the input DNA/RNA amount and to check sample quality at
appropriate steps of the sequencing workﬂow, the second most com-
monly used appliance represents the ﬂuorometer, which offers ﬂuo-
rometric quantitation. Most frequently used devices for this purpose
are the Thermo Fisher Scientiﬁc Qubit Fluorometer and the NanoDrop.
Hence, there are two different options available for quality assessment
during deﬁned sequencing workﬂow steps, nonetheless it is recom-
mend utilizing both appliances (Simbolo et al., 2013). Since most
sequencing protocols recommend at least one of both devices for QC,
it is up to the respective laboratory whether they use only one or
both, dependent on their quality standards and regulations. Moreover,
for accurate quantiﬁcation of DNA/RNA at certain workﬂow steps and
for determining the ﬁnal library quantity, established systems such as
quantitative PCR (qPCR) or digital droplet PCR (ddPCR) are recom-
mended (Robin et al., 2016).
4.5. Spike-in controls for downstream quality evaluation
Another recommended and already established standard is the
spike-in control. It is a matter of a well-known and validated reference
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quencing workﬂow in order to identify errors during data analysis
(Ledergerber and Dessimoz, 2011). This control is carried along the
whole process and undergoes the same handling steps as the investigat-
ed sample, from initial quantiﬁcation to ﬁnal downstream processing. If
a sequence error is observed in the reference control, the same error
occurred in all likelihood in the main sample. Therefore, the spike-in
control is considered to be a benchmark for sample quality. A suitable
reference is the genomic DNAof bacteriophageφX174. Due to commen-
surable straightforward cultivation and the quite small genome of
merely 5386 nucleotides (Michel et al., 2010), which needs much less
space on a sequencing ﬂow cell, the use of φX174 is convenient. More-
over, RNA sequencing applications offer already a set of established RNA
spike-in controls developed by the External RNA Controls Consortium
(ERCC) (Baker et al., 2005). These RNA standards consist on the same
principles as the abovementionedDNA controls but undergo in contrast
more handling steps of library preparation anddeliver therefore a better
performance reﬂection of the endogenous sample (Jiang et al., 2011).
5. Standard proposals for sequence data handling, processing and
storage
5.1. The impact and classiﬁcation of sequencing errors
With establishment of NGS some new challenges were ahead. In
comparison to largely standardized Sanger sequencing, the quality per
base was generally lower, which decreased the speciﬁcity of polymor-
phism detection. Sanger sequencing is considered as being a well-
established automated sequencingmethod and as current gold standard
for variant identiﬁcation and it is possible to get access to well charac-
terized reference samples where reliable data are available in order to
ensure analytical validity (Grada and Weinbrecht, 2013; McCourt
et al., 2013; Tsiatis et al., 2010). Due to novel high-throughput opportu-
nities, the pooling of samples was in many cases required to improve
the efﬁciency but led on the other hand to different concentrations be-
tween different samples. This inﬂuenced the sensitivity of a given assay.
Additionally, biases and miscalls, respectively undercalls and overcalls
occurred during target enrichment via PCR because of polymerase er-
rors (Brockman et al., 2008). Compared to Sanger sequencing, polymer-
ase errors in NGS have an impact on the overall error rate of the system.
One of themain error sources represents the noise in a system, which is
produced through different aspects within a run. In case of 454 plat-
forms these aspects includes optical and chemical noise, multiple tem-
plates on one bead, signal contamination from nearby wells and a loss
of synchrony between the large amount of template copies on each
bead as well as homopolymeric sequence runs (Brockman et al.,
2008). Moreover, Schmutz et al. proposed different error deﬁnitions
and error events in a bioinformatics context (Schmutz et al., 2004). Con-
tiguous insertion, deletion or an erroneous run of multiple base pairs
were deﬁned as a single error event, whereas amisassembly considered
whole sequences. A signiﬁcant error counts as a single error as well but
was deﬁned as at least 50 contiguous incorrect base pairs, which led to
the deﬁnition of the base pair error.
5.2. Downstream bioinformatics pipeline and data analysis
The advent of NGS technologies led to a lot of different ﬁle formats,
some of them established as standards or de facto standards over time.
One of these common ﬁle formats represents FASTQ. Each sequencing
platform is able to generate a FASTQ ﬁle during the downstream pro-
cessing, which is equipped with the Phred score, an associated per
base quality score which is based on an estimated error probability
(Cock et al., 2010) (see Appendix A— Table A.3). The FASTQ ﬁle format
was established for functioning as an extension to FASTA, characterized
by aforementioned Phred score for each base in a sequence, plus an op-
tional line for comments. This optional comment/description lineshould be thereby standardized by containing all additional and essen-
tial information regarding the sample. Currently, the FASTQ format and
corresponding Phred scores are not determined as ofﬁcial standards,
but actually work as unwritten de facto standards for base qualities
due to most widely acceptance as cross-platform interchange ﬁle for-
mat, since establishment of Sanger sequencing (Cock et al., 2010).
Moreover, QUAL is another introduced ﬁle format, which stores appro-
priate Phred scores and accompanies to FASTA ﬁles, especially in NGS.
Access to particular Phred quality scores might be beneﬁcial for objec-
tive comparisons between different sequencing platforms and repre-
sents directly a criterion for QC, respectively quality documentation.
The equivalent de facto standard for variant calls is the Variant Call For-
mat (VCF), which established during the 1000 Genomes Project and
plays a pivotal role especially in clinical sequencing applications
(Rehm et al., 2013). A VCF ﬁle stores information about sequence varia-
tions like Indels (insertions or deletions) or single nucleotide polymor-
phisms (SNP's) together with comprehensive annotation (Danecek
et al., 2011). An additional standardized ﬁle formatwhich emerged dur-
ing the 1000Genomes Project, represents the Sequence Alignment/Map
(SAM) format, which includes read alignments against a reference
sequence, whereby SAM is nowadays substituted, respectively used in
addition to the Binary Alignment/Map (BAM) format, the compressed
analogue to the SAM format (Li et al., 2009). The generated output
ﬁles after a sequencing run have to be analyzed and annotated in the
downstream bioinformatics pipeline using appropriate software. One
common tool is FASTQC, which evaluates the quality of sequencing re-
sults for FASTQ ﬁles using statistical tests (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). However, there is a vast variety of ad-
ditional QC software available, such as NGS QC Toolkit (Patel and Jain,
2012), QC-Chain (Zhou et al., 2013) or ChromaPipe (Otto et al., 2008).
For speciﬁc VCF data validation and annotation, regarding variant
calls, multiple realignments or genotyping, theGenomeAnalysis Toolkit
(GATK) represents an often used framework (McKenna et al., 2010).5.3. Data submission requirements and standards
After completion of data QC, analysis and annotation, the next step
faces the submission of ﬁnal ﬁles to customers or public databases. To
address the standard minimum requirements for submission of gener-
ated and downstream analyzed, respectively annotated NGS data,
Chain et al. recommend an overall coverage of at least 90% for sequence
data and a formof gap resolution tominimize the number of contigs and
scaffolds (Chain et al., 2009). Additionally, they suggest the veriﬁcation
and correction of annotation procedures regarding anomalies in coding
regions to improve the comparability of genes. To address especially the
genomic sequence annotation, the Genomic Standards Consortium
(GSC) developed and published the Minimum Information about a
Genome Sequence (MIGS) speciﬁcation in order to remedy the lack of
incomplete genome descriptions (Field et al., 2008). Due to the emerg-
ing ﬁeld of metagenomics, adequate sequence descriptions are crucial
for respective approaches. Besides common sequencing parameters
like depth of coverage or overall quality, the MIGS speciﬁcation also
lists information referring to a broader biological context such as taxon-
omy, trophic level or propagation. Moreover, the current gold standard
for sequence data is described with properties such as at most 1 error
per 10,000 base pairs (pursuant to 99.99% accuracy) and assembly of
each replicon into a single contig, while all sequences are complete
and have been reviewed and edited (Chain et al., 2009; Schmutz et al.,
2004). The determined accuracy of 99.99% is part of the Bermuda Stan-
dards, which were established during the Human Genome Project
(HGP) meeting in 1997 and acts as a standard for sequence ﬁdelity
(http://web.ornl.gov/sci/techresources/Human_Genome/research/
bermuda.shtml). The second Bermuda Standard prescribes that the
sequence should be contiguous, so gaps are not left out. Consensus
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2004).
5.4. Further considerations for NGS data handling
Standardization of genome source, library construction, hierarchical
sequencing strategies and deﬁnition of what means “ﬁnished”, paired
with a centralized QC center are additional suggestions with the aim
to improve sequence quality (Schmutz et al., 2004). Especially the cen-
tralized QC center would exert an advantageous inﬂuence on sequence
ﬁdelity by evaluating different techniques, rather than independent
technique examination by each center for itself. Consequently, this cen-
ter could distribute reviews and test performance reports for technolog-
ical developments in order to serve each prospect sequencing service
with up to date information and innovations. Furthermore, the coverage
across the sample and the percentage of bases that meet the required
minimum coverage threshold are among those aspects, which should
deﬁne a high quality value for different samples. Therefore, every labo-
ratory is encouraged to set a minimum coverage, especially in medical
applications, where high quality variant calls are an absolute require-
ment. Additionally, the percentage of aligned reads, percentage of
unique reads, percentage of bases corresponding to targeted sequences,
uniformity of coverage, density of clusters and percentage of targeted
bases with no coverage are possible data quality features (Rehm et al.,
2013).
6. Conclusions
There is still a long road ahead to the establishment of a general stan-
dard in NGS. The ﬁrst problem faces the standardization contributions
from a global point of view. NGS originated from the US and shows
the broadest distribution there, thus the overwhelming majority of
standardization efforts are based overseas. In contrast, veriﬁable respec-
tively published approaches from other countries do not exist at this
time. Therefore, international initiatives should be found and encour-
aged to participate in this ﬁeld, especially addressing the considerable
presence of European standardization bodies like the European
Committee for Standardization (CEN). An additional obstacle of stan-
dardization represents the validity of standards across different NGS
applications. It became obvious that the current focus relies on NGS
standardization in clinical diagnostics due to highest demands and re-
quirements regardingQC and data reliability in this area. The same stan-
dards which will be determined for clinical sequencing would not be
necessarily applicable or reasonable in e.g. plant genome sequencing
and vice versa. However, once standardization reaches an advanced sta-
tus the established standards will be adopted for other applications,
whereby the formulation of standards will likely accelerate at this
stage. In order to address opportunities for future work in NGS stan-
dardization, one reasonable next step could be the development of a
comprehensive Failure Mode and Effects Analysis (FMEA) in contem-
plation of standardizing QA aspects for NGS. The FMEA serves as a
fault prevention strategy for recognition of potential error sources and
the immediate reaction to these errors at an earliest stage within a pro-
cess. The authors developed a ﬁrst draft of a FMEA dealing with stan-
dardization of QA aspects for ion semiconductor sequencing, which is
on request available.Moreover, once standardization reaches amore so-
phisticated level, the subsequent step will be the automation of whole
sample and library preparation on a consolidated platform. This will in-
troduce the feasibility to parallelize several platform-independent NGS
workﬂows conducive to improving cost and time efﬁciency as well as
increasing throughput. Finally, in order to mention an upcoming appli-
cation of NGS, Parson et al. performed a project to evaluate high-
throughputmitochondrial DNA (mtDNA) sequencing useful for forensic
analysis (Parson et al., 2013). Originallymanaged by Sanger sequencing
the nowadays possibilities of NGS enable expeditiously and economical
investigation of mitochondrial genome information as it is alreadyachieved by Illumina's recent MiSeq FGx sequencer (Caratti et al.,
2015). These speciﬁc targets provide haplotype-speciﬁc patterns of mu-
tations and thus build the basis for QC of novel mtDNA data in order to
apply NGS in forensics (Parson et al., 2013).
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Questions and speciﬁcations of a generic TN for the fragmentation step in NGS experi-
ments. The ofﬁcial approval number is assembled out of sample strain notation and date
of order, whereby precise sample identiﬁcation is possible at each process step. The last
row comprises only the bare necessities with reference to other appropriate TN's (i.e. TN
with detailed speciﬁcations and parameters about a device or kit). Another important as-
pect concerns the documentation of barcode sequences within the TN in order to track
pooled samples (Head et al., 2014).Question Speciﬁcationho performed fragmentation of the sample? 1) Name, title
2) Position
3) Areas of responsibilityhat sample was fragmented? 1) Sample source
2) Starting material
3) Ofﬁcial approval numberhen was the sample fragmented? 1) Time
2) Date
3) Signaturehere was the sample fragmented? 1) Company
2) Department
3) Laboratory
4) Postal addresshy was the sample fragmented? 1) Order number
2) Date of orderow was the sample fragmented? 1) Devices/Materials/Kits
2) Device parameters
3) Results of quantiﬁcation
4) Speciﬁcation of quality controls
5) ReferencesTable A.2
Upstream analytical process accreditation requirements as published by CAP's NGSWork
Group MOL (Aziz et al., 2015). The table summarizes seven laboratory checklist require-
ments for the wet bench process in NGS experiments.MOL topic Description Requirementsocumentation Use of SOP All standard operating protocols
must be documented in order to
trace each step and manipulations
All used methods, reagents,
instruments, instrument software
and versions have to be documented
Controls need to be described
Targeted NGS assays and
target-enrichment protocols, regard-
ing captured regions must be
documented
Development of SOP for each vali-
dated sample type
Sequence information of barcodes
for pooled analysis must be
documented
Metrics and QC parameters regard-
ing run performance have to be doc-
umented (% of reads mapping to
target region, base quality and cov-
erage thresholds, average(continued on next page)
T T






coverage/base and target region)
Deﬁnition and documentation of
acceptance and rejection criteria for
sample preparation and sequencing
Documentation of regions that failed
analysis






4Analytic performance of NGS proce-
dures must be validated
Determination of optimal assay
conditions and analysis settings in






Validation of each sample type
Determination of a minimum
number of samples, dependent on
sample, target, assay and application
Revalidation of minor changes such
as new reagent charges
Documentation of lot numbers
Revalidation of major changes such
as new sequencing system or
different target enrichment methodM Use of documented QM
programDevelopment of a QM plan
QA program must be written and
compliance has to be documented
QA program should assess all parts of
a workﬂow
QA program should be embedded
within overall QMS
Quality program should address
general problems, especially in case
of nonconformance with laboratories
own policies and procedures
Quality program should encourage
scientiﬁc and laboratory staff to
interchange about quality issuesonﬁrmatory
testingUse of policy for
documentation of
conﬁrmatory testingEstablished policy that clearly
documents indications for
conﬁrmatory testing
Each laboratory has to show
evidence of monitoring their NGS
assaysboratory
recordsUse of laboratory records
for identiﬁcation and
trace of samplesDocumentation of all reagents,
primers, sequencing chemistries and
platforms
Description of performed test
comprising targeted sequence and
depth of coverage
Citing publications or websites
Maintaining a documentation
systemxception log Use of exception log for
monitoring deviations
from SOPDocumentation of any deviation
from SOP, the reason for deviation
and the outcome
Extensive consultation with
laboratory supervisor or laboratory




Changes or modiﬁcations in SOP
should be supported by two quali-
ﬁed staff members and have to be
signed by the laboratory directoronitoring of




upgradesImplementation of policy to monitor
and integrate upgrades to
instruments, sequencing chemistries
and reagents/kits
Validation of introduced up-to-date
instruments or reagents/kitsable A.2 (continued)MOL topic Description Requirements
Addressing methods which are used
to monitor upgradesTable A.3
Overview of Phred quality scores and the corresponding base calling accuracies. The table
shows different Phred scores, the probability of an incorrect base call aswell as the respec-
tive accuracy per base for the appropriate quality scores. Q30, i.e. 99.9% accuracy or 1 error
per 1000 bases, is generally considered to be a benchmark for quality (http://
www.illumina.com/documents/products/technotes/technote_Q-Scores.pdf).Phred quality score Probability of incorrect base call Base call accuracy0 1 in 10 90%
0 1 in 100 99%
0 1 in 1000 99.9%
0 1 in 10,000 99.99%
0 1 in 100,000 99.999%5References
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